Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.47 USD | +1.26% | +0.58% | +17.40% |
Jun. 11 | Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing | MT |
May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.40% | 2.03B | |
-9.24% | 11.6B | |
-4.32% | 8.11B | |
+6.07% | 5.67B | |
+30.76% | 5.62B | |
-14.91% | 3.89B | |
+11.39% | 2.68B | |
-61.44% | 2.58B | |
-8.32% | 2.26B | |
-6.79% | 1.82B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating